Investigating disruptive, healthy and brain electrical activity responses to effective psychological trauma treatments

Adult patients from a health center specialized in the treatment of psychological trauma; eye movement desensitization and reprocessing therapy or EMDR; conventional therapy given by the center; electroencephalographic or EEG response, symptoms of post-traumatic stress or PTSD, complex PTSD or CPTSD, borderline personality disorder or BPD, and post-traumatic growth or PTG (TEEPCBG)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN91146045

Enrollment

108

Registered

2021-05-21

Start date

2021-05-02

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disruptive and healthy responses related to psychological trauma: post-traumatic stress disorder (PTSD), complex post-traumatic stress disorder (cPTSD), borderline personality disorder (BPD), post-traumatic growth (PTG) Mental and Behavioural Disorders Post-traumatic stress disorder, emotionally unstable personality disorder

Interventions

Patients from the Center for Applied Psychology of the University of Talca will be randomly included in one of the 2 clinical trial groups: 1. EMDR treatment 2. Conventional center treatment Both gro

2)". The responsible researcher will also be the one who matches both groups of therapies according to risk factors (sex, educational level, belonging to minorities, psychiatric comorbidities, and his

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Current participant inclusion criteria as of 05/04/2024: 1. Aged between 18 and 59 years 2. Exposed to at least one traumatic event Previous participant inclusion criteria: 1. Aged between 18 and 70 years 2. Exposed to at least one traumatic event

Exclusion criteria

Exclusion criteria: 1. Recent (within the previous 6 months) suicide attempt 2. Severe psychiatric comorbidities (such as schizophrenia) 3. Requiring hospitalization 4. Problem drug or alcohol use 5. High dissociation

Design outcomes

Primary

Measure	Time frame
1. Electrical activity of the brain measured using the Biosemi 64-channel electroencephalography (EEG) system at baseline, in the middle of treatment, at the end of treatment, and 4 months after treatment 2. Post-traumatic Stress Disorder (PTSD) measured using the Post-traumatic Stress Disorder Checklist-Civilian version (PCL-C) at baseline, in the middle of treatment, at the end of treatment, and 4 months after treatment 3. Complex Post-traumatic Stress Disorder (cPTSD) measured using the International Trauma Questionnaire (ITQ) at baseline, in the middle of treatment, at the end of treatment, and 4 months after treatment 4. Borderline Personality Disorder (BPD) measured using the Personality Assessment Inventory-Borderline Scale (PAI-BOR) at baseline, in the middle of treatment, at the end of treatment, and 4 months after treatment 5. Post-traumatic growth measured using the Post-Traumatic Growth Inventory (PTGI) at baseline, in the middle of treatment, at the end of treatment, and 4 months after treatment	—

Measure

Time frame

1. Electrical activity of the brain measured using the Biosemi 64-channel electroencephalography (EEG) system at baseline, in the middle of treatment, at the end of treatment, and 4 months after treatment 2. Post-traumatic Stress Disorder (PTSD) measured using the Post-traumatic Stress Disorder Checklist-Civilian version (PCL-C) at baseline, in the middle of treatment, at the end of treatment, and 4 months after treatment 3. Complex Post-traumatic Stress Disorder (cPTSD) measured using the International Trauma Questionnaire (ITQ) at baseline, in the middle of treatment, at the end of treatment, and 4 months after treatment 4. Borderline Personality Disorder (BPD) measured using the Personality Assessment Inventory-Borderline Scale (PAI-BOR) at baseline, in the middle of treatment, at the end of treatment, and 4 months after treatment 5. Post-traumatic growth measured using the Post-Traumatic Growth Inventory (PTGI) at baseline, in the middle of treatment, at the end of treatment, and 4 months after treatment

—

Secondary

Measure	Time frame
1. Disturbance measured using the Subjective Units of Disturbance Scale (SUD) at baseline, in the middle of treatment, at the end of treatment, and 4 months after treatment 2. Dissociation measured using the Dissociation Experiences Scale (DES) at baseline, in the middle of treatment, at the end of treatment, and 4 months after treatment 3. Traumatic events measured using the Life Events Checklist for DSM-5 (LEC-5) at baseline, in the middle of treatment, at the end of treatment, and 4 months after treatment 4. Depression measured using the Patient Health Questionnaire (PHQ-9) at baseline, in the middle of treatment, at the end of treatment, and 4 months after treatment	—

Measure

Time frame

1. Disturbance measured using the Subjective Units of Disturbance Scale (SUD) at baseline, in the middle of treatment, at the end of treatment, and 4 months after treatment 2. Dissociation measured using the Dissociation Experiences Scale (DES) at baseline, in the middle of treatment, at the end of treatment, and 4 months after treatment 3. Traumatic events measured using the Life Events Checklist for DSM-5 (LEC-5) at baseline, in the middle of treatment, at the end of treatment, and 4 months after treatment 4. Depression measured using the Patient Health Questionnaire (PHQ-9) at baseline, in the middle of treatment, at the end of treatment, and 4 months after treatment

—

Countries

Chile

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026